Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors

Int J Clin Pharmacol Ther. 2012 Jan;50(1):76-8. doi: 10.5414/cpp50076.
No abstract available

Publication types

  • Clinical Trial, Phase I

MeSH terms

  • Disease Progression
  • Female
  • Humans
  • Male
  • Maximum Tolerated Dose
  • Neoplasms / genetics
  • Neoplasms / pathology
  • Neoplasms / therapy*
  • Protein Kinase C / genetics*
  • RNA, Small Interfering / administration & dosage
  • RNA, Small Interfering / pharmacology*
  • Treatment Outcome

Substances

  • RNA, Small Interfering
  • protein kinase N
  • Protein Kinase C
  • Atu027